Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Vulnerable brains can be steered towards healthy development

Sep. 4, 2019

Grunenthal and UniQuest establish neuropathic pain collaboration

Sep. 3, 2019

Suven evaluates SUVN-G3031 in phase II trial for narcolepsy with and without cataplexy

Sep. 3, 2019

TREM2 correlates with slow decline in AD

Sep. 3, 2019

Daiichi Sankyo presents new analgesics

Sep. 3, 2019

Eicosis' soluble epoxide hydrolase inhibitor EC-5026 to enter the clinic

Sep. 3, 2019

Alcohol consumption is deceased with FGFR1 inhibition in rodents

Sep. 3, 2019

New phase I trial to study gene therapy for APOE4 homozygotes with Alzheimer's disease

Sep. 2, 2019

Biogen initiates phase I study of BIIB-094 in patients with Parkinson's disease

Sep. 2, 2019

ASCLEPIOS I and II trials of ofatumumab in relapsing MS meet primary endpoint

Aug. 30, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...